MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Multiple system atrophy(MSA): Treatment"

  • 2018 International Congress

    Atypical Response to Apomorphine in a Patient with Multiple System Atrophy

    S. Ozben, F. Genc, F. Tuter Yilmaz, A. Erdal, N. Atis (Antalya, Turkey)

    Objective: Multiple system atrophy (MSA) is a sporadic neurodegenerative disease clinically characterized by cerebellar signs, parkinsonism and autonomic dysfunction. MSA is classified into two sub-types;…
  • 2018 International Congress

    Effects of mannitol treatment in a mice model of multiple system atrophy (MSA)

    N. Lev, Y. Barhum (Kfar Saba, Israel)

    Objective: The aim of this study was to examine the effect of mannitol treatment in a mice model of MSA. Background: Alpha-synuclein aggregation represents the…
  • 2018 International Congress

    Rapamycin for treating MSA: A preclinical proof of concept study

    M. Lopez-Cuina, P. Guerin, E. Bezard, W. Meissner, P-O. Fernagut (Bordeaux, France)

    Objective: To assess the effects of rapamycin on motor behavior, α-synuclein burden and surrogate markers of neurodegeneration in a transgenic mouse model of multiple system…
  • 2018 International Congress

    Patient Perspective in Multiple System Atrophy

    A. Mahajan, Z. Mari (Detroit, MI, USA)

    Objective: To report patient and/ or caregiver perspective in Multiple System Atrophy (MSA). Background: The majority of literature on MSA’s natural history comes from single…
  • 2018 International Congress

    Is safinamide useful for atypical Parkinsonian syndromes?

    M. Machío Castelló, M. Oses Lara, C. Feliz Feliz, J. del Val, P. García Ruiz (Madrid, Spain)

    Objective: Seeking new treatment strategies in atypical Parkinsonian syndromes Background: Atypical parkinsonian syndromes (APS) include several entities leading to parkinsonism with atypical features such as…
  • 2018 International Congress

    The role of deep brain stimulation targeting GPi in patients with multiple system atrophy

    P. Hedera, D. Claassen, D. Isaacs (Nashville, TN, USA)

    Objective: To report clinical outcomes of two patients diagnosed with MSA-P who underwent bilateral deep brain stimulation (DBS). Background: The role of DBS in patients…
  • 2018 International Congress

    PBT434 prevents the accumulation of glial cell inclusions and insoluble alpha-synuclein in a mouse model of Multiple System Atrophy

    D. Finkelstein, P. Adlard, N. Stefanova, D. Stamler (Parkville, Vic, Australia)

    Objective: To evaluate PBT434 in a transgenic mouse model of multiple system atrophy (MSA) Background: PBT434 is a novel quinazolinone inhibitor of iron-mediated protein accumulation…
  • 2018 International Congress

    Effects of multi-session repetitive transcranial magnetic stimulation on performance of motor control and dynamics of spontaneous brain activity in multiple system atrophy

    Z. Liu, H.Z. Ma, X.M. Wang, Z. Wang, Y.Q. Wang, J.H. Zhou, T. Feng (Beijing, China)

    Objective: To explore the effectiveness of repetitive transcranial magnetic stimulation (rTMS) on performance of motor control and dynamics of spontaneous brain activity in multiple system…
  • 2018 International Congress

    Caregiver Burden in a Multidisciplinary MSA Clinic

    M. Salinas, E. Kent, S. Vernino, P. Khemani (Dallas, TX, USA)

    Objective: To explore the correlation between disease and caregiver burden in MSA. Background: For patients with Multiple System Atrophy (MSA), the increasing loss of independence…
  • 2018 International Congress

    Preclinical cardiovascular sympathoexcitatory effects of TD-9855, a novel norepinephrine transporter (NET) inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with primary autonomic failure

    S. Hegde, M. Pulido-Rios, A. McNamara, J. Smith, W. Smith, J. Kanodia, D. Bourdet (South San Francisco, CA, USA)

    Objective: TD-9855 is a novel NET inhibitor (1) being studied for the treatment of symptomatic nOH. The objective of the present study was to characterize…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley